EGFR Antibody (E-8): sc-374607

EGFR Antibody (E-8) is a mouse monoclonal IgG2b antibody that detects a peptide mapping within a C-terminal cytoplasmic domain of EGFR of human origin in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). EGFR plays a crucial role in cell signaling and is primarily located on the cell membrane, where EGFR functions as a receptor tyrosine kinase. This strategic positioning allows EGFR to effectively bind to ligands, such as epidermal growth factor (EGF) and transforming growth factor alpha (TGFα), initiating a cascade of intracellular signaling pathways that regulate cell proliferation, differentiation, and survival. EGFR signaling is integral to processes like wound healing, where EGFR promotes keratinocyte migration and proliferation to restore tissue integrity. Furthermore, EGFR plays a key role during embryonic development, ensuring proper organ formation and cellular differentiation. EGFR′s membrane location is essential, as activation leads to receptor internalization and subsequent degradation, a process vital for maintaining cellular homeostasis. Dysregulation of EGFR signaling is often implicated in various cancers, making EGFR a significant target for therapeutic intervention. By utilizing anti-EGFR antibody (E-8), researchers can gain insights into EGFR′s role in both normal physiology and disease states, furthering understanding of EGFR′s potential as a biomarker and therapeutic target in oncology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

EGFR Antibody (E-8) References:

1. [EGFR and gefitinib (Iressa)].  |  Noro, R. and Gemma, A. 2008. Gan To Kagaku Ryoho. 35: 1076-9. PMID: 18633244
2. [Status of components in EGFR-related signal transduction as predictive markers for anti-EGFR antibody therapy in colorectal cancer treatment].  |  Shimodaira, H., et al. 2009. Gan To Kagaku Ryoho. 36: 1063-6. PMID: 19620792
3. EGFR: tale of the C-terminal tail.  |  Gajiwala, KS. 2013. Protein Sci. 22: 995-9. PMID: 23674349
4. Endocytosis of EGFR requires its kinase activity and N-terminal transmembrane dimerization motif.  |  Heukers, R., et al. 2013. J Cell Sci. 126: 4900-12. PMID: 23943881
5. Evolution of the EGFR pathway in Metazoa and its diversification in the planarian Schmidtea mediterranea.  |  Barberán, S., et al. 2016. Sci Rep. 6: 28071. PMID: 27325311
6. Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors.  |  Thomas, R., et al. 2019. Int J Mol Sci. 20: PMID: 31121829
7. In Situ Hybridization (ISH) Combined with Immunocytochemistry (ICC) Co-detection of Phosphorylated EGFR in A431 Cultured Cells.  |  Hagen, J., et al. 2023. Methods Mol Biol. 2593: 213-220. PMID: 36513933
8. QM/MM Simulations of Afatinib-EGFR Addition: The Role of β-Dimethylaminomethyl Substitution.  |  Ma, S., et al. 2024. J Chem Theory Comput. 20: 5528-5538. PMID: 38877999
9. Structural insights into the role and targeting of EGFRvIII.  |  Bagchi, A., et al. 2024. Structure. 32: 1367-1380.e6. PMID: 38908376

The preferred EGFR antibody is EGFR Antibody (528): sc-120.